Clinical Application of Tumor-specific Anti-tumor Immunity Induced by Tumor Cells Expressing Fas (CD95) Ligand
Clinical Application of Tumor-specific Anti-tumor Immunity Induced by Tumor Cells Expressing Fas (CD95) Ligand
批准号:
13557097
负责人:
TAKEDA Yasutaka
金额:
$8.83万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
2001
资助国家:
日本
项目状态:
已结题
起止时间:
2001 至 2003
中文摘要
点击翻译按钮获取中文摘要
英文摘要
CD95 ligand (FasL)-expressing tumors cause immunopotentiation following vigorous neutrophil infiltration. Thus, the induction of neutrophil Infiltration by FasL appears to play an important role in tumor rejection. 1) The mechanism by which FasL-expressing tumors cause neutrophil infiltration has not been well understood. Here, we Investigated the role of chemokines in FasL-induced antitumor activity. CXC chemokine receptor 2 (CXCR2) knockout (KO) mice are a powerful tool for studying CXC chemokine-mediate neutrophil infiltration. Thus, we examined the mechanism for the neutrophil recruitment Induced by FasLcDNA-transfected MethA (MethA+FasL) fibrosarcoma using CXCR2 KO mice. MethA+FasL cells were completely rejected in wild-type (WT) and KO mice. MethA+FasL cells Injected i.p. induced the recruitment of both neutrophils and macrophages in peritoneal cavity (PC) of WT but only macrophages in PC of KO mice, although CXC and CC chemokines were released In PC in both mice. Macrophages Inc … More ubated with MethA+FasL cells released CXC and CC chemokines. F4/80-positive macrophages decreased after injection of MethA+FasL cells. Macrophages derived from WI and KO but not neutrophils from WT mice induced the recruitment of neutrophils when adoptively i.p. transferred with MethA+FasL cells into FasL/Fas-deficient mice. The different recruitment of inflammatory cells between WT and KO mice was attributed to bone marrow (BM) cells by BM transfer experiment. These results demonstrated that CXC chemokines are essential for neutrophil recruitment and that macrophages but not neutrophils play a critical role in FasL-induced infiltration of Inflammatory cells and that chemokines played important roles In eradication of FasL-expressing tumor cells and induction of antitumor immunity. 2) Mouse mammary tumor, BJMC3879, has highly metastatic potential. FasLcDNA-transfected BJMC3879 (BJMC+FasL) was established for clinical application of breast cancer. Although It induced neutrophil recruitment, It was not rejected In WT mice. The reason might be that BJMC+FasL was little expressed FasL-protein on cell surface. It could be indicated that the capability of FasL-protein expression depends on a kind of tumor cell. 3) On the other hand, we were developing non-viral vectors for clinical application. We are investigating the effects of Quarternary complex (Qplex) (cDNA+cationlc liposome+protamine+transferin) or polyethilenimine on transfecting rate of a few cell lines. Several problems for clinical application become clear. Less
期刊论文(56)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Takeda, Y.: "Does the timing of surgery for breast cancer in relation to the menstrual cycle or geomagnetic activity affect prognoses of premenopausal patients ?."Biomed.Pharmacother.. 57(Supp). 96-103 (2003)
Takeda, Y.:“与月经周期或地磁活动相关的乳腺癌手术时机是否会影响绝经前患者的预后?”Biomed.Pharmacother.. 57(增刊)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
清水本武: "アポトーシスのすべてアポトーシス制御による治療法:悪性腫瘍"臨床免疫. 38巻特別増刊号. 404-408 (2002)
Mototake Shimizu:“关于细胞凋亡。通过控制细胞凋亡进行治疗:恶性肿瘤”《临床免疫学》第 38 卷特刊(2002 年)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Shimizu M, Yoshimoto T, Matsuzawa A, Takeda T.: "Modification of tumor cells with Fas (CD95) antigen gene and Fas ligand (CD95L) gene transfection by electroporation for Immunotherapy of cancer."Mol.Biotechnol.. 25. 79-87 (2003)
Shimizu M、Yoshimoto T、Matsuzawa A、Takeda T.:“通过电穿孔用 Fas (CD95) 抗原基因和 Fas 配体 (CD95L) 基因转染对肿瘤细胞进行修饰,用于癌症的免疫治疗。”Mol.Biotechnol.. 25. 79-
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Eriguchi M, Levi F, Hisa T, Yanagie H, Nonaka Y, Takeda Y.: "Chronothetrapy for cancer."Biomed. Pharmacother.. 57 (Supp). 92-95 (2003)
Eriguchi M、Levi F、Hisa T、Yanagie H、Nonaka Y、Takeda Y.:“癌症的计时疗法”。Biomed。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Toyota, H.: "Calpain-induced Bax-cleavage product is a more potent inducer of apoptotic cell death than wild-type Bax"Cancer Lett.. 189. 221-230 (2003)
Toyota, H.:“钙蛋白酶诱导的 Bax 裂解产物是比野生型 Bax 更有效的细胞凋亡诱导剂”Cancer Lett.. 189. 221-230 (2003)
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
共 24 条
Basic study for Analysis of Intractable Resistant Tumor Cells and their Overcoming in Cancer Gene Therapy
-
批准号:14571125
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.24万
-
财政年份:2002
-
负责人:TAKEDA Yasutaka
-
依托单位:
Basic study for. Cancer Gene Therapy by Antitumor Effects Using Fas-Fas Ligand-Mediated Apoptosis
-
批准号:12671144
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.11万
-
财政年份:2000
-
负责人:TAKEDA Yasutaka
-
依托单位:
A study for cancer gene therapy through Fas-mediated apoptosis
-
批准号:10671099
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.18万
-
财政年份:1998
-
负责人:TAKEDA Yasutaka
-
依托单位:
A study on tumor cell/cell interactions using mouse mammary tumor models
-
批准号:08671337
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$1.41万
-
财政年份:1996
-
负责人:TAKEDA Yasutaka
-
依托单位:
Study of Tumor Progression in vivo and in vitro using
-
批准号:06671186
-
项目类别:Grant-in-Aid for General Scientific Research (C)
-
资助金额:$1.41万
-
财政年份:1994
-
负责人:TAKEDA Yasutaka
-
依托单位:
海外基金